The method was found to be specific for PTX in the presence of degradation products with an overall analytical run time of ~ 9 min. Accuracy reported as % bias was found to be 0.1-2.5% bias for all samples tested. Intra-assay precision (repeatability) was found to be 0.22-2.65% RSD, while inter-day precision (intermediate precision) was found to be 1.0-3.0% RSD for the samples studied. The calibration curve was found to be linear with the equation y = 29.78x + 7.65, and a linear regression coefficient of 0.9994 over the concentration range 0.05-20 µg/mL. The limits of quantitation and detection were 0.05 and 0.02 µg/mL, respectively. Taxol (30 mg/5 mL), a commercially available dosage form of PTX, was assayed and 100.6-103.6% of the label claim was recovered.
Introduction
Paclitaxel (taxol or PTX) ( Figure 1 ) (1) is a taxane derivative originally derived in limited amounts from the bark of the pacific yew tree Taxus brevifolia (Taxaceae). It is now obtained from a taxane precursor derived from the needles of the European yew, Taxus bacata, using a semi-synthetic process. It is a BCS class IV drug with a high degree of hydrophobicity and consequently an extremely low aqueous solubility of 4 µg/mL (2, 3) . PTX has shown significant activity against a wide range of tumors such as those in breast, ovarian, and lung cancer, in addition to head and neck carcinomas (4) . Capillary electrophoresis (5), liquid-chromatography-mass spectrometry (6, 7) , and high-performance liquid chromatography (HPLC) (8) (9) (10) (11) methods for the quantitative determination of PTX in biological samples have been reported. These methods are not directly applicable for the determination of PTX in pharmaceutical dosage forms and need further investigation, particularly for method development and validation. In recent years, some HPLC methods (12) (13) (14) for the determination of PTX in pharmaceutical dosage forms have also been published. Although these methods can be used for the determination of PTX in the presence of its related substances, none are stability-indicating. Furthermore, the analysis time of the analytical methods used for the quality control of formulated PTX are long (12, 13) and require multi-step sample treatment (14) that is laborious and time-consuming. Ciutaru et al. have published a validated method for the determination of the related impurities of PTX in pharmaceutical dosage forms (15) . The method, reported in the current United States Pharmacopoeia (USP) (16) , requires the use of gradient elution with a mobile phase of water and acetonitrile. There is no information published in the USP with respect to the stability-indicating nature of the method. Stability is important from a quality control perspective in the pharmaceutical industry, and therefore any analytical method developed should preferably be stability-indicating. To our knowledge, no validated stability-indicating analytical method for the determination of PTX in pharmaceutical dosage forms has been reported in the literature. Therefore, an isocratic stability-indicating HPLC method for the rapid quantitative determination of PTX in presence of degradation products in pharmaceutical dosage forms was developed. This paper reports the forced degradation of PTX under stress conditions including acid and base hydrolysis, oxidation, heat, and UV light. This manuscript also reports the validation of the method for the accurate assay of PTX in a commercially available pharmaceutical dosage form without interference from Cremophor EL (polyoxyethylated castor oil), a component of the formulation.
Experimental
Chemicals and reagents PTX (99.95% purity) was kindly supplied by Cipla (India) and was used without further purification. Taxol (30 mg/5 mL) was obtained from Bristol-Meyer Squibb's (Canada). Methanol, sodium hydroxide, hydrochloric acid, and hydrogen peroxide were obtained from Merck (Darmstadt, Germany). All reagents used were at least of analytical grade, except methanol, which was HPLC grade. HPLC-grade water was obtained following distillation in glass and passage through a Milli-Q system (Millipore, Milford, MA) and was used to prepare all solutions.
HPLC instrumentation and conditions
Chromatographic analyses were performed using an Agilent HPLC system that consisted of a model G1311A quaternary HPLC pump (Agilent Technologies, Palo Alto, CA), a model G1329A autosampler system (Agilent Technologies) fitted with a 20 µL sample loop, and a model G1315B diode array detector (Agilent Technologies).
Chromatographic data were monitored and analyzed using Agilent ChemStation software (Agilent Technologies). Separation of the compounds of interest was achieved using a Nucleosil RP-18 (5 µm, 250 × 4.0 mm) analytical column protected by a C 18 Nucleosil precolumn (5 µm, 4.0 × 4.0 mm). The mobile phase was comprised of methanol-water in a ratio of 80:20 v/v and was delivered at a flow rate of 1.0 mL/min, and the eluent was monitored at a wavelength of 230 nm. The column was maintained at ambient temperature (25ºC) and 20 µL samples were introduced onto the HPLC system every 15 min. The mobile phase was filtered through a 0.45 µm Chrom Tech Nylon-66 filter prior to use.
Preparation of stock and standard solutions
A stock solution of PTX (1 mg/mL) was prepared in methanol. The stock solution was protected from light using aluminium foil and stored for 7 days at 4ºC with no evidence of decomposition. Aliquots of the standard stock solution of PTX were transferred into 10-mL A-grade volumetric flasks using A-grade bulb pipettes and the solutions were made up to volume with mobile phase to yield solutions with final concentrations of 0.05, 0.1, 0.5, 1, 6, and 20 µg/mL.
Preparation of commercial products for assay
The content of three ampoules of the relevant commercial product were poured into a volumetric flask and mixed well. One hundred microliters of the resultant solution was added into each of six 100-mL volumetric flasks, made up to volume with mobile phase, and mixed well to yield a 6 µg/mL solution of PTX.
Forced degradation studies of PTX
In order to assure the selectivity of the method and to provide an indication of the stability-indicating properties of the proposed method, pure active pharmaceutical ingredient (API) of PTX was stressed under various conditions to conduct forced degradation studies (17) . PTX is insoluble in water, soluble in ethanol, and freely soluble and stable in methanol. Therefore, methanol was selected as a co-solvent in all forced degradation studies. All solutions for use in forced degradation studies were prepared by dissolving the API in an equal volume of methanol and solutions of aqueous hydrogen peroxide, distilled water, hydrochloric acid, or sodium hydroxide to achieve a concentration of 120 µg/mL of PTX. Following degradation, the solutions were diluted with mobile phase (80:20) to yield concentrations of ~ 6 µg/mL for PTX.
Oxidation studies
Solutions for use in oxidation studies were prepared in methanol and 10% H 2 O 2 (50:50 v/v), and the resultant solutions were analyzed 4 days after preparation.
Acid degradation studies
During initial forced degradation studies, it was observed that acid and base hydrolysis of PTX occurred rapidly and that complete degradation of drug had taken place when the resultant solution was analyzed 24 h after preparation. Therefore, for all subsequent experiments, the exposure time was decreased to 5 h. Solutions for acid degradation studies were prepared in methanol and 1M hydrochloric acid (50:50, v/v), and the resultant solutions were analyzed 5 h after preparation.
Alkali degradation studies
Solutions for alkali degradation studies were prepared in methanol and 0.1M sodium hydroxide (50:50 v/v), and the resultant solutions analyzed 5 h after preparation.
Neutral degradation studies
Solutions for neutral degradation studies were prepared in methanol and water (50:50 v/v), and the resultant solutions protected from light for 24 h prior to analysis.
Temperature stress studies
PTX was exposed to dry heat (150ºC) in a convection oven for 24 h and was then prepared for analysis as previously described.
Photostability studies
PTX powder and solutions of drug were prepared and exposed to light to determine the effects of irradiation on the stability of PTX in solution and in the solid state. Approximately 50 mg of PTX was spread onto a glass dish in a layer that was less than 2 mm in thickness. A solution of PTX (120 µg/mL) was prepared in methanol and HPLC-grade water (50:50, v/v). All samples for photostability testing were placed in a light cabinet (Suntest CPS/CPS + , Atlas Material Testing Technology, Germany) and exposed to light for 30 h, resulting in an overall illumination of ≥ 200 w.h/m 2 at 25ºC with UV radiation in the range 320-400 nm. Control samples were protected from light with aluminium foil and then exposed to light in the light cabinet. Exposure of all samples was concurrent. Following removal of the samples from the light cabinet, samples were prepared for analysis as previously described.
Results and Discussion

HPLC method development and optimization
A Nucleosil RP-18 (5 µm, 250 × 4.0 mm) analytical column protected by a C 18 Nucleosil precolumn (5 µm, 4.0 × 4.0 mm) maintained at ambient temperature (25ºC) was used for the separation and the method validated for the determination of PTX in Taxol injections. The composition and the flow rate of the mobile phase were changed to optimize the separation conditions using the stressed samples. A mobile phase consisting of methanol and water (80:20, v/v) set at a flow rate of 1 mL/min was ultimately selected for use for further studies after preliminary chromatographic separations. In terms of determining the most appropriate and acceptable separation conditions, the optimization of gradient elution is more complex than for isocratic methods because there are more variables that can influence the selectivity (primarily gradient steepness, initial eluent strength, and secondarily dwell volume) of the method (18) . In addition, the transfer of a gradient elution method between columns, instruments, and laboratories is notoriously a more difficult (19) and inherently slower technique than isocratic methods. Furthermore, many chromatographers have experienced "ghost" peaks (20) , baseline noise (21) , and other disturbances (e.g., eluent mixing) associated with gradient elution that can lead to inaccurate determination of peak area and peak height, thereby preventing the accurate and precise quantitation of the compound of interest. Under the experimental conditions described, all peaks of interest were well defined and free from tailing. The effects of small deliberate changes in the mobile phase composition and flow rate were evaluated as a part method robustness testing.
Validation of the method
The analytical method was validated with respect to several parameters including linearity, limit of quantitation (LOQ), limit of detection (LOD), precision, accuracy, selectivity, recovery, and robustness/ruggedness (22,23).
Linearity
Linearity was established by least squares linear regression analysis of the calibration curve (24, 25) . The calibration curves (n = 3) that were constructed for PTX were linear over the concentrations of 0.05, 0.1, 0.5, 1, 6, and 20 µg/mL. Peak areas of PTX were plotted versus concentration and linear regression analysis performed on the resultant curves. Three correlation coefficients of R1 = 0.9994, R2 = 0.9993, and R3 = 0.9991 with % relative standard deviation (RSD) values ranging from 0.2-3% across the concentration range studied were obtained following linear regression analysis. Typically, the regression equation for the calibration curve was found to be y = 29.78X + 7.65.
LOQ and LOD
The LOQ was determined as the lowest amount of analyte that was reproducibly quantified above the baseline noise following triplicate injection. The resultant % RSD for these studies was ≤ 0.35%. The LOQ that produced the requisite precision and accuracy was found to be 50 ng/mL. The LOD was determined based on signal-to-noise ratio using an analytical response of three times the background noise (26) . The LOD for PTX was found to be 20 ng/mL using this method. In a previously published method (13) for the determination of PTX in pharmaceutical dosage forms, the LOQ and LOD of the method were found to be 240 and 72 ng/mL, respectively. Recently, two other HPLC methods (12, 14) developed for the determination of PTX in pharmaceutical dosage forms have also been published, and neither the LOQ nor the LOD were reported.
Precision
The intra-and inter-day variability or precision data are summarized in Table I and were assessed by the use of standard solutions of three different concentrations of drug. Repeatability or intra-day precision was investigated by injecting nine replicate samples of PTX solutions of three different concentrations. Inter-day precision was assessed by injecting the same three samples over three consecutive days. The data reported in Table I reveal that the method precision has a RSD below 2.13% for intra-assay precision and 2.20% for inter-assay precision. In a previously published method (13) for the determination of PTX in pharmaceutical dosage forms, the RSD for repeatability and intermediate precision were determined to be below 1% and 0.76%, respectively. 
Accuracy
Accuracy data for the assay following the determination of PTX are summarized in Table II . Accuracy was determined by interpolation of replicate (n = 6) peak areas of three accuracy standards (0.05, 1, and 20 µg/mL) from a calibration curve that had been freshly prepared as previously described. In each case, the percent relative error and accuracy were calculated and found to be less than 2.5%. In a previously published method (13) , accuracy determined in the interval 80-120% of the working concentration of the PTX and evaluated by the parameter "recovery" was within the proposed limits (100 ± 2%), with results ranging from 98.2% to 100.5% and a RSD of 0.83%.
Specificity
The results of stress testing studies indicated a high degree of specificity of this method for PTX. Taxol injection is a clear colorless to slightly yellow viscous solution. It is supplied as a nonaqueous solution intended for dilution with a suitable parenteral fluid prior to intravenous infusion. Taxol is available in 30 mg (5 mL), 100 mg (16.7 mL), and 300 mg (50 mL) multidose vials. Each mL of sterile nonpyrogenic solution contains 6 mg paclitaxel, 527 mg of purified Cremophor EL, and 49.7% (v/v) dehydrated alcohol. Peak purity values for PTX in chromatograms of stressed samples and Taxol injections were in the range of 0.999-1, indicating that the peaks were homogenous, thereby establishing the selectivity of this assay method. Typical chromatograms obtained following the assay of untreated PTX and stressed PTX solutions are shown in Figure 2 .
Ruggedness and robustness tests
As recommended in the International Conference on Harmonization (ICH) Guidelines, a robustness assessment was performed during the development of the analytical method (27) . The ruggedness (28) of the method is assessed by comparison of the intra-and inter-day assay results for PTX that were performed by two analysts in two different laboratories. The % RSD values for intra-and inter-day assays of PTX in the Taxol injections performed in the two different laboratories by two analysts did not exceed 3.5%, indicating the ruggedness of the method. In addition, the robustness of the method was investigated under a variety of conditions including changes to flow rate, laboratory temperature, and eluent composition (29) . The degree of reproducibility of the results obtained as a result of small but deliberate variations in these method para-meters in addition to changing the analyst proves that the method is robust. The percent recoveries of PTX in Table III are good under most conditions and did not show a significant change when the critical parameters were modified.
Results of forced degradation studies
All stressed samples tested in the solid state and in solution remained colorless following exposure, and PTX was found to be completely stable under oxidative ( Figure 2D ) and neutral ( Figure 2F ) stress conditions, whereas exposure of PTX to alkaline ( Figure  2C ) conditions in methanol and 0.1M sodium hydroxide (50:50 v/v) resulted in 100% decomposition within 5 h. On the other hand, PTX decomposed with a resultant 12%, 18%, and 50% degradation under photolytic ( Figure  2E ), acidic ( Figure 2G ), and thermal ( Figure  2B ) stress conditions, respectively. The major impurity formed under thermal stress in the solid state was observed to be 7-epi-taxol, the thermodynamically more stable isomer ( Figure 2B ). It was not the intention of the study to identify degradation products of API and excipients but merely to show that they would not interfere if and when present. Peak purity results determined using diode array detection confirm that the PTX peak is homogeneous and pure in all stress samples. The percentage recoveries of PTX are presented in Table IV . The stability of the stock solution was determined by quantitation of drug in solution in comparison to the response obtained for freshly prepared standard solutions. No significant changes (< 1%) were observed for the chromatographic responses for the stock solutions relative to freshly prepared standards.
Assay
The validated analytical method was applied to the determination of PTX in commercially available Taxol injections. Figure 3 depicts typical HPLC chromatograms obtained following the analysis of Taxol injections (A) and from a standard solution (B). The peak at 4.5 min is a related substance of PTX. The sources of the PTX API and PTX, which were used for the preparation of the injectable formulation were the same. The concentration of standard solution and assay solution is the same; therefore, the peak is visible in both chromatograms. The results of the assay (n = 6) yielded 101.17% (% RSD = 1.20%) of label claim for PTX. The observed concentration of PTX was found to be 6.070 ± 0.073 µg/mL (mean ± SD). The mean retention time of PTX was 6.17 min with associated % RSD values of 0.10%. The results of the assay indicate that the method is selective for the analysis of PTX without interference from the excipients used to formulate and produce these dosage forms. Peak purity values for PTX in chromatograms of injection samples were in the range of 0.999-1, indicating that the peaks were homogenous, thereby establishing the selectivity of this assay method.
Conclusions
A simple, rapid, accurate, and precise stability-indicating HPLC analytical method has been developed and validated for the routine analysis of PTX in raw material and injectable dosage forms. The results of stress testing, undertaken according to the ICH guidelines, reveal that the method is selective and stability-indicating. The proposed method has the ability to separate this drug from its degradation products and can be applied to the analysis of samples obtained during accelerated stability experiments. 
